Search

Site-specific delivery of chemotherapeutics using actively targeted-stimuli-responsive liposomes is a promising approach to enhance the therapeutic efficiency of anti-cancer drugs while reducing the associated undesirable side effects. Recently, the co-functionalization of liposomes has shown interesting results in enhancing cellular uptake; however, such systems suffer from stability issues. This study proposes mixing calcein-loaded liposomes decorated with different ligands, namely estrone and Herceptin, to treat breast cancer. We investigated the low-frequency ultrasound-mediated release of calcein from the synthesized liposomes (control, estrone-modified, Herceptin-modified, and mixed estrone and Herceptin liposomes at different volume fractions). The results showed that the release increased as the power density increased and that estrone-conjugated liposomes achieved the highest release under all test conditions.

Delivering highly toxic drugs inside a safe carrier to tumors while achieving controlled and effective drug release at the targeted sites represents an attractive approach to enhance drug efficiency while reducing its undesirable side effects. Functionalization of highly biocompatible nanocarriers such as liposomes conjugated with targeting moieties enhances their ability to target specific cancer cells overexpressing the targeted receptors. Furthermore, upon their accumulation at the target site, high-frequency ultrasound (HFUS) can be used to stimulate the controlled release of the loaded drugs. Here, the US-mediated drug release from calcein-loaded non-pegylated, pegylated as well as targeted-pegylated liposomes modified with human serum albumin (HSA) and transferrin (Tf) was investigated. HFUS at two different frequencies (1 MHz and 3 MHz) was found to trigger calcein release, with higher release rates recorded at the lower frequency (i.e., 1 MHz) compared to the higher frequency (i.e., 3 MHz) despite a higher power density. Pegylation was found to enhance liposomal sensitivity to HFUS. In addition, targeted pegylated liposomes were more susceptible to HFUS than non-targeted pegylated (control) liposomes. These findings show that pegylation and targeting moieties directly influence liposomal sensitivity to HFUS. Therefore, combining targeted-pegylated liposomes with HFUS represents a promising controlled and effective drug delivery system.

Functionalized liposomes are among the most promising antineoplastic agents delivery vehicles. Contemporaneous to their accretion at the tumor site, they need to be potentiated to release their cargo using a suitable triggering modality. In this work, targeted Doxorubicin (DOX)-loaded stealth liposomes were synthesized and functionalized with Human Serum Albumin (HSA) to target the overexpressed HSA receptors (HSA-Rs). The effects of low-frequency ultrasound (LFUS) in inducing DOX release from the synthesized liposomes were investigated In Vitro. DOX release increased with the increasing power density of ultrasound. HSA conjugation to the liposomes increased their sensitivity to LFUS. Furthermore, HSA conjugation also enhanced the liposome’s cytotoxic activity and uptake by the cancer cells overexpressing HSA-Rs. This cytotoxic activity and cellular uptake were further enhanced by triggering drug release from those targeted liposomes using LFUS. Combining HSA-targeted liposomes with LFUS is a promising approach in drug delivery.

In this study, the flexible aluminum-based MIL-53(Al) metal-organic framework was loaded with doxorubicin (DOX) and naproxen (NAP) and was examined as a promising pH/ultrasound dual-responsive drug delivery system. The two drugs were encapsulated in MIL-53(Al) individually to produce the DOX@MIL-53(Al) and NAP@MIL-53(Al) nanocarriers. They were also encapsulated as a dual-drug formulation to produce the DOX* + NAP*@MIL-53(Al) nanocarrier. The MOF nanoparticles were characterized using the Scanning Electron Microscopy (SEM), X-ray diffraction (XRD), Fourier Transform Infrared spectroscopy (FTIR), and Dynamic Light Scattering (DLS) techniques. In the case of the DOX@MIL, the nanocarriers’ drug Encapsulation Efficiency (EE) and Encapsulation Capacity (EC) were 92% and 16 wt.%, respectively, whereas, in the case of NAP@MIL-53(Al), the average NAP EE and EC were around 97.7% and 8.5 wt.%, respectively. On the other hand, in the DOX* + NAP*@MIL-53(Al) nanoparticles, the average DOX* EE and EC were 38.9% and 6.22 wt.%, respectively, while for NAP*, the average EE and EC were 70.2% and 4.49 wt.%, respectively. In vitro release experiments demonstrated the good pH and Ultrasound (US) dual-responsiveness of these nanocarriers, with a maximum US-triggered DOX and NAP release, at a pH level of 7.4, of approximately 53% and 95%, respectively. In comparison, the measured release was around 90% and 36% at pH 5.3 for DOX and NAP, respectively. In the case of the dualdrug formulation, the nanocarrier displayed similar pH/US dual-responsive behavior. Finally, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) results confirmed the biocompatibility and low cytotoxicity of MIL-53(Al) at concentrations up to 1000 μg/ml.

The human nervous system is one of the most complex systems of the human body. Understanding its behavior is crucial in drug discovery and developing medical devices. One approach to understanding such a system is to model its most basic unit, neurons. The leaky integrate and fire (LIF) method models the neurons’ response to a stimulus. Given the fact that the model’s equation is a linear ordinary differential equation, the purpose of this research is to compare which numerical analysis method gives the best results for the simplified version of this model. Adams predictor and corrector (AB4-AM4) and Heun’s methods were then used to solve the equation. In addition, this study further researches the effects of different current input models on the LIF’s voltage output. In terms of the computational time, Heun’s method was 0.01191 s on average which is much less than that of the AB-AM4 method (0.057138) for a constant DC input. As for the root mean square error, the AB-AM4 method had a much lower value (0.0061) compared to that of Heun’s method (0.3272) for the same constant input. Therefore, our results show that Heun’s method is best suited for the simplified LIF model since it had the lowest computation time of 36 ms, was stable over a larger range, and had an accuracy of 72% for the varying sinusoidal current input model.

Diabetes is sweeping the world as a silent epidemic, posing a growing threat to public health. Modeling diabetes is an effective method to monitor the increasing prevalence of diabetes and develop cost-effective strategies that control the incidence of diabetes and its complications. This paper focuses on a mathematical model known as the diabetes complication (DC) model. The DC model is analyzed using different numerical methods to monitor the diabetic population over time. This is by analyzing the model using five different numerical methods. Furthermore, the effect of the time step size and the various parameters affecting the diabetic situation is examined. The DC model is dependent on some parameters whose values play a vital role in the convergence of the model. Thus, parametric analysis was implemented and later discussed in this paper. Essentially, the Runge–Kutta (RK) method provides the highest accuracy. Moreover, Adam–Moulton’s method also provides good results. Ultimately, a comprehensive understanding of the development of diabetes complications after diagnosis is provided in this paper. The results can be used to understand how to improve the overall public health of a country, as governments ought to develop effective strategic initiatives for the screening and treatment of diabetes.

Background: Metal-organic frameworks (MOFs), as attractive hybrid crystalline porous materials, are being increasingly investigated in biomedical applications owing to their exceptional properties, including high porosity, ultrahigh surface areas, tailorable composition and structure, and tunability and surface functionality. Of interest, in this review, is the design and development of MOF-based drug delivery systems (DDSs) that have excellent biocompatibility, good stability under physiological conditions, high drug loading capacity, and controlled/targeted drug release. Objective: This review highlights the latest advances in MOFs as anticancer drug delivery systems (DDSs) along with insights on their design, fabrication, and performance under different stimuli that are either internal or external. The synthesis methods of MOFs, along with their advantages and disadvantages, are briefly discussed. The emergence of multifunctional MOF-based theranostic platforms is also discussed. Finally, the future challenges facing the developments of MOFs in the field of drug delivery are discussed. Methods: The review was prepared by carrying out a comprehensive literature survey using relevant work published in various scientific databases. Results: Novel MOFs in biomedical applications, especially in drug delivery, have shown great potential. MOF-based DDSs can be classified into normal (non-controllable) DDSs, stimuli-responsive DDSs, and theranostic platforms. The normal DDSs are pristine MOFs loaded with therapeutic agents and offer little to no control over drug release. Stimuli-responsive DDSs offer better spatiotemporal control over drug release by responding to either endogenous (pH, redox, ions, ATP) or exogenous stimuli (light, magnetism, US, pressure, temperature). The theranostic platforms combine stimuli-responsive drug delivery with diagnostic imaging functionality, paving the road for imaging-guided drug delivery. Conclusion: This review presented a summary of the various methods utilized in MOF's synthesis along with the advantages and disadvantages of each method. Furthermore, the review highlighted and discussed the latest developments in the field of MOF-based DDSs and theranostic platforms. The review is focused on the characteristics of MOF-based DDSs, the encapsulation of different anticancer drugs as well as their stimuli-responsive release.

Mathematical modeling has been used to simulate the interaction of chemotherapy and immunotherapy drugs intervention with the dynamics of tumor cells growth. This work studies the interaction of cells in the immune system, such as the natural killer, dendritic, and cytotoxic CD8+ T cells, with chemotherapy. Four different cases were considered in the simulation: no drug intervention, independent interventions (either chemotherapy or immunotherapy), and combined interventions of chemotherapy and immunotherapy. The system of ordinary differential equations was initially solved using the Runge-Kutta method and compared with two additional methods: the Explicit Euler and Heun’s methods. Results showed that the combined intervention is more effective compared to the other cases. In addition, when compared with Runge-Kutta, the Heun’s method presented a better accuracy than the Explicit Euler technique. The proposed mathematical model can be used as a tool to improve cancer treatments and targeted therapy.

Background: Existing cancer treatment methods have many undesirable side effects that greatly reduce the quality of life of cancer patients. Objective: This review will focus on the use of ultrasound-responsive liposomes and polymeric micelles in cancer therapy. Methods: This review presents a survey of the literature regarding ultrasound-triggered micelles and liposomes using articles recently published in various journals, as well as some new patents in this field. Results: Nanoparticles have proven promising as cancer theranostic tools. Nanoparticles are selective in nature, have reduced toxicity, and controllable drug release patterns making them ideal carriers for anticancer drugs. Numerous nanocarriers have been designed to combat malignancies, including liposomes, micelles, dendrimers, solid nanoparticles, quantum dots, gold nanoparticles, and, more recently, metal-organic frameworks. The temporal and spatial release of therapeutic agents from these nanostructures can be controlled using internal and external triggers, including pH, enzymes, redox, temperature, magnetic and electromagnetic waves, and ultrasound. Ultrasound is an attractive modality because it is non-invasive, can be focused on the diseased site, and has a synergistic effect with anticancer drugs. Conclusion: The functionalization of micellar and liposomal surfaces with targeting moieties and the use of ultrasound as a triggering mechanism can help improve the selectivity and enable the spatiotemporal control of drug release from nanocarriers.

Water scarcity is an increasing problem on every continent, which instigated the search for novel ways to provide clean water suitable for human use; one such way is desalination. Desalination refers to the process of purifying salts and contaminants to produce water suitable for domestic and industrial applications. Due to the high costs and energy consumption associated with some desalination techniques, membrane-based technologies have emerged as a promising alternative water treatment, due to their high energy efficiency, operational simplicity, and lower cost. However, membrane fouling is a major challenge to membrane-based separation as it has detrimental effects on the membrane’s performance and integrity. Based on the type of accumulated foulants, fouling can be classified into particulate, organic, inorganic, and biofouling. Biofouling is considered the most problematic among the four fouling categories. Therefore, proper characterization and prediction of biofouling are essential for creating efficient control and mitigation strategies to minimize the damage associated with biofouling. Moreover, the use of artificial intelligence (AI) in predicting membrane fouling has garnered a great deal of attention due to its adaptive capability and prediction accuracy. This paper presents an overview of the membrane biofouling mechanisms, characterization techniques, and predictive methods with a focus on AI-based techniques, and mitigation strategies.

Nanocarriers, such as liposomes and micelles, were developed to enhance the delivery of therapeutic drugs to malignant tissues. Internal or external stimuli can be applied to achieve spatiotemporal controlled release from these carriers. This will result in enhancing their therapeutic efficacy while reducing toxicity. Mathematical modeling is used to simulate drug release from nanocarriers; this will facilitate and optimize the development and design of desirable nanocarriers in a systematic manner, rather than a trial-and-error approach. This review summarizes nine mathematical models often used to simulate drug release from nanocarriers and reviews studies which employed these models to simulate drug release from conventional as well as temperature-, pH-, and ultrasound-triggered micelles and liposomes.

Over the past few decades, immunotherapy has emerged as a promising therapeutic approach to treat some types of cancer. Moreover, antibody-based cancer therapies can trigger apoptosis and cell growth inhibition to induce immune cell destruction of target cells through antibody-dependent cellular cytotoxicity (ADCC). Nevertheless, immunotherapeutic efficiency is often restricted due to deficient delivery or low accumulation of therapeutic molecules at the tumor site. The development of pegylated liposomes with monoclonal antibodies conjugated to their surfaces (immunoliposomes) and triggered with ultrasound can effectively improve drug accessibility by enhancing cell membrane permeability and drug release. This review summarizes existing traditional cancer treatments and their limitations, emphasizing the recent advancements in ultrasound-triggered immunotherapy.

[Image: see text] The delivery of chemotherapeutics to solid tumors using smart drug delivery systems (SDDSs) takes advantage of the unique physiology of tumors (i.e., disordered structure, leaky vasculature, abnormal extracellular matrix (ECM), and limited lymphatic drainage) to deliver anticancer drugs with reduced systemic side effects. Liposomes are the most promising of such SDDSs and have been well investigated for cancer therapy. To improve the specificity, bioavailability, and anticancer efficacy of liposomes at the diseased sites, other strategies such as targeting ligands and stimulus-sensitive liposomes have been developed. This review highlights relevant surface functionalization techniques and stimuli-mediated drug release for enhanced delivery of anticancer agents at tumor sites, with a special focus on dual functionalization and design of multistimuli responsive liposomes.

Targeted liposomes enable the delivery of encapsulated chemotherapeutics to tumours by targeting specific receptors overexpressed on the surfaces of cancer cells; this helps in reducing the systemic side effects associated with the cytotoxic agents. Upon reaching the targeted site, these liposomes can be triggered to release their payloads using internal or external triggers. In this study, we investigate the use of low-frequency ultrasound as an external modality to trigger the release of a model drug (calcein) from non-targeted and targeted pegylated liposomes modified with cyclic arginine-glycine-aspartate (cRGD). Liposomes were exposed to sonication at 20-kHz using three different power densities (6.2, 9, and 10 mW/cm

In this study, we investigated the interactions between SARS-CoV-2 and miRNAs associated with lung cancer using bioinformatic approaches. A special focus was placed on TMPRSS2 and lung cancer progression pathways involving AKT/PI3K/PTEN genes.

Existing cancer treatments are often accompanied by adverse side effects that can greatly reduce the quality of life of cancer patients; this sets the platform for the development and application of nanocarrier-based platforms for the delivery of anticancer drugs. Among these nanocarriers, liposomes have demonstrated excellent potential in drug delivery applications. Furthermore, the overexpression of certain receptors on cancer cells has led to the development of active targeting approaches where liposome surfaces are decorated with ligands against these receptors. Given the central role that sugars play in cancer biology, more and more researchers are integrating “glycoscience” into their anticancer therapeutic designs. Carbohydrate functionalized liposomes present an attractive drug delivery system due to their biocompatibility, biodegradability, low toxicity, and specific cell targeting ability. This review presents an overview of the preparation methods, characterization, evaluation, and applications of carbohydrate functionalized liposomes in cancer therapy.

The successful targeting of tumors can be achieved by conjugating targeting moieties to nanoparticles. These modifications allow nannocarriers to achieve greater targeting specificity through binding to specific receptors overexpressed on the surface of the tumor cells. In this study, pegylated liposomes encapsulating the model drug/dye calcein and conjugated to hyaluronic acid (HA) molecules were successfully synthesized, and their ability to target HA receptors overexpressed on a breast cancer cell line was investigated in vitro. Low-frequency ultrasound (LFUS), applied at three different power densities (6.2, 9, and 10 mW/cm2) were used to trigger the release of the entrapped calcein. Both the control and HAconjugated liposomes showed similar release profiles. HA conjugation to the liposomes resulted in a significant increase in calcein uptake by the breast cancer cell line MDA-MB-231 known for its CD44 (HA receptor) overexpression, while such an effect was not recorded with NIH-3T3, an embryonic mouse fibroblast, with low levels of CD44 expression. The application of low LFUS showed a significant enhancement of calcein uptake by MDA-MB-231 cells from our liposome compared to calcein uptake without cell exposure to ultrasound. These findings suggest that combining HA-conjugated liposomes with ultrasound is a promising drug delivery platform in breast cancer treatment.

The use of ultrasound as a medical diagnostic tool began in the 1940s. Ever since, the medical applications of ultrasound have included imaging, tumor ablation, and lithotripsy; however, an ever-increasing body of literature demonstrates that ultrasound has potential in other medical applications, including targeted drug delivery. Site-specific drug delivery involves delivering drugs to diseased areas with a high degree of precision, which is particularly advantageous in cancer treatment as it would minimize the adverse side effects experienced by patients. This review addresses the ability of ultrasound to induce localized and controlled drug release from nanocarriers, namely micelles and liposomes, utilizing thermal and/or mechanical effects. The interactions of ultrasound with micelles and liposomes, the effects of the lipid composition, and ultrasound parameters on the release of encapsulated drugs are discussed. In addition, a survey of the literature detailing some in vitro and in vivo ultrasound triggered drug delivery systems is presented.

Immunoliposomes have emerged as attractive drug targeting vehicles for cancer treatment. This review presents the recent advances in the design of immunoliposomes encapsulating a variety of chemotherapeutic agents. We provided an overview of different routes that can be used to conjugate antibodies to the surfaces of liposomes, as well as several examples of stimuliresponsive immunoliposome systems and their therapeutic potential for cancer treatment.

Liposomes are designed to encapsulate chemotherapy drugs used in cancer treatment. Their small size (nano-scale) allows them to extravagate through the leaky vascular surroundings of the tumor. Ultrasound waves can be used as an external trigger to control drug release from these liposomes. It is essential that the therapeutic dose is released as cancer cells can develop drug resistance, in part due to the concentration levels of the chemotherapeutic agent dipping below therapeutic levels during the treatment. To address this issue, this study proposes a feedback drug release controller based on model predictive control theory (MPC) and neural networks (NN). Our preliminary simulation results suggest that using a feedback controller is capable of keeping drug concentration levels, in the tumor site, at or above therapeutic levels. This is achieved by controlling the amount of acoustic drug release from these lipid-based nanocarriers, thus ensuring a controlled, safe, and effective therapeutic dose.

This paper researches a suitable mathematical model that can reliably predict the release of a model drug (namely calcein) from biologically targeted liposomal nanocarriers triggered by ultrasound. Using mathematical models, curve fitting is performed on a set of five experimental acoustic drug release runs from Albumin-, Estrone-, and RGD-based Drug Delivery Systems (DDS). The three moieties were chosen to target specific cancers using receptor-mediated endocytosis. The best-fitting mathematical model is then enhanced using a Kalman filtering (KF) algorithm to account for the statistics of the dynamic and measurements noise sequences in predicted drug release. Unbiased drug-release estimates are realized by implementing an online noise identification algorithm. The algorithm is first deployed in a simulated environment in which it was rigorously tested and compared with the correct solution. Then, the algorithm was used to process the five experimental datasets. The results suggest that the Adaptive Kalman Filter (AKF) is exceptionally good at handling drug release estimation problems with a priori unknown or with changing noise covariances. In comparison with the KF, the AKF approach exhibited as low as a 69% reduction in the level of error in estimating the drug release state. Finally, the proposed algorithm is not computationally demanding and is capable of online estimation tasks.

To improve currently available cancer treatments, nanomaterials are employed as smart drug delivery vehicles that can be engineered to locally target cancer cells and respond to stimuli. Nanocarriers can entrap chemotherapeutic drugs and deliver them to the diseased site, reducing the side effects associated with the systemic administration of conventional anticancer drugs. Upon accumulation in the tumor cells, the nanocarriers need to be potentiated to release their therapeutic cargo. Stimulation can be through endogenous or exogenous modalities, such as temperature, electromagnetic irradiation, ultrasound (US), pH, or enzymes. This review discusses the acoustic stimulation of different sonosensitive liposomal formulations. Emulsion liposomes, or eLiposomes, are liposomes encapsulating phase-changing nanoemulsion droplets, which promote acoustic droplet vaporization (ADV) upon sonication. This gives eLiposomes the advantage of delivering the encapsulated drug at low intensities and short exposure times relative to liposomes. Other formulations integrating microbubbles and nanobubbles are also discussed.

Typical methods used in cancer treatment, including chemotherapy, are debilitating because of the various adverse side effects experienced by cancer patients. The free drug injected into the patient at given doses affects both healthy and cancerous cells. Therefore, novel methods are being researched to ensure the selectivity of the treatment. The purpose of this study is to test the release of a model fluorescent drug, calcein, from echogenic stealth liposomes, triggered by lowfrequency pulsed ultrasound. Several experimental parameters related to the ultrasound (US) and the investigated liposomes were varied in order to examine their effect on the acoustic release. Upon analysis of experimental results, the study concluded that release can be maximized by optimizing the sonication frequency, power density, and US pulse duration. When a non-isothermal chamber is used to conduct the experiments, it is important to have longer ‘Off’ than ‘On’ US periods in order to avoid overheating the liposomes. Applying such pulsation pattern can also be utilized to achieve slower release rates, which safely meet the desired drug levels at the end of the session. Our study also concluded that optimizing the liposome concentration is vital to delivering desired drug doses. Additionally, the type of lipids used in the synthesis should be carefully selected to produce stable yet acoustically sensitive liposomes capable of releasing at desired rates.

Doxorubicin (DOX) is one of the most widely used anthracycline anticancer drugs due to its high efficacy and evident antitumoral activity on several cancer types. However, its effective utilization is hindered by the adverse side effects associated with its administration, the detriment to the patients’ quality of life, and general toxicity to healthy fast-dividing cells. Thus, delivering DOX to the tumor site encapsulated inside nanocarrier-based systems is an area of research that has garnered colossal interest in targeted medicine. Nanoparticles can be used as vehicles for the localized delivery and release of DOX, decreasing the effects on neighboring healthy cells and providing more control over the drug’s release and distribution. This review presents an overview of DOX-based nanocarrier delivery systems, covering loading methods, release rate, and the cytotoxicity of liposomal, micellar, and metal organic frameworks (MOFs) platforms.

Targeted liposomes triggered by ultrasound are a promising drug delivery system as they potentially improve the clinical outcomes of chemotherapy while reducing associated side effects. In this work, a comprehensive model fitting was performed for a large dataset of liposomal release profiles with seven targeting moieties (albumin, cRGD, estrone, hyaluronic acid, Herceptin, lactobionic acid, and transferrin) in addition to the control liposomes under ultrasound release protocols. Two levels of ultrasound frequencies were tested: low frequency (20 kHz) at 6.2, 9, and 10 mW/cm2 as well as high frequencies (1.07 MHz and 3 MHz) at 10.5 and 173 W/cm2. At a low frequency, Hixson–Crowell, Korsmeyer–Peppas, Gompertz, Weibull, and Lu–Hagen showed good fits to our release profiles at all three power densities. At high frequencies, the former three models reflected the best fit. These models will aid in predicting drug release profiles for future in vitro studies.

In this work, liposome-coated iron (III) benzene-1,3,5-tricarboxylate (Fe-BTC) metal-organic framework is examined as a promising pH/Ultrasound dual-responsive nanocarriers for doxorubicin (DOX) delivery. The successful coating of the MOF particles (Lip-Fe-BTC) with the phospholipid bilayer (PBL) was established by direct fusion into the synthesized liposomes. The liposome coating was verified using several techniques, including dynamic light scattering (DLS) and transmission electron microscopy (TEM). The DLS measurements showed an increase in the average particle diameter of liposomes from 150 nm to 163.1 nm for Lip-Fe-BTC particles. The Fe-BTC particles had the highest average particle diameter (287.3 nm). These results demonstrated that the PBL reduced the aggregation of the particles and improved their dispersity in the release medium. The TGA results demonstrated the MOF's excellent thermal stability. Furthermore, the nanocarrier's loading efficiency and capacity were determined to be ~90% and ~13.5 wt%, respectively. The in-vitro DOX release experiments demonstrated that the DOX-loaded Fe-BTC and liposome-coated Fe-BTC particles showed good pH and US dual-responsive capability, making them promising nanocarriers for drug delivery. The application of US enhanced DOX release from both Fe-BTC and liposome-coated Fe-BTC. In the case of Fe-BTC-DOX particles, the application of US enhanced the DOX release to around 38% and 67%, at pH levels of 7.4 and 5.3, respectively. Similarly, DOX release from the Lip-Fe-BTC-DOX particles reached ~35% and ~53%, at pH levels of 7.4 and 5.3, respectively. The MTT assay showed the biocompatibility and low cytotoxicity of these nanocarriers below 100 µg/ml.

[Image: see text] In this study, we investigated the interactions between SARS-CoV-2 and miRNAs associated with lung cancer using bioinformatic approaches. A special focus was placed on TMPRSS2 and lung cancer progression pathways involving AKT/PI3K/PTEN genes.

The use of targeted liposomes encapsulating chemotherapy drugs enhances the specific targeting of cancer cells, thus reducing the side effects of these drugs and providing patient-friendly chemotherapy treatment. Targeted pegylated (stealth) liposomes have the ability to safely deliver their loaded drugs to the cancer cells by targeting specific receptors overly expressed on the surface of these cells. Applying ultrasound as an external stimulus will safely trigger drug release from these liposomes in a controlled manner. In this study, we investigated the release kinetics of the model drug "calcein" from targeted liposomes sonicated with low-frequency ultrasound (20 kHz). Our results showed that pegylated liposomes were more sonosensitive compared to nonpegylated liposomes. A comparison of the effect of three targeting moieties conjugated to the surface of pegylated liposomes, namely human serum albumin (HSA), transferrin (Tf) and arginylglycylaspartic acid (RGD), on calcein release kinetics was conducted. The fluorescent results showed that HSA-PEG and Tf-PEG liposomes were more sonosensitive (showing higher calcein release following the exposure to pulsed LFUS) compared to the control pegylated liposomes, thus adding more acoustic benefits to their targeting efficacy.